Cell Death and Differentiation (2016), 1–12

www.nature.com/cdd

RETRACTED

IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy

X Fang[1,2], J-H Jeong[2], X Long[1,2], S-J Park[2], D Wang[2], M Shuai[1,2], R Wei[1,2], C Li[1], S Li[1], S Zhang[1], MB Duran[2], K-W Lo[3], SW Tsao[4], R Glaser[5], Z Luo[6], X Feng*[,1,2], Y Tian*[,1] and J-L Luo*[,1,2]

Radioresistance is a major obstacle in successful clinical cancer radiotherapy, and the underlying mechanisms are not clear. Here we show that IKKα-mediated miR-196a biogenesis via interaction with Drosha regulates the sensitivity of nasopharyngeal carcinoma (NPC) cells to radiotherapy. Phosphorylation of IKKα at T23 site (p-IKKαT23) promotes the binding of IKKα to Drosha that accelerates the processing of miR-196a primary transcripts, leading to increased expressions of both precursor and mature miR-196a. Dephosphorylation of p-IKKαT23 downregulates miR-196a expression and promotes the resistance of NPC cells to radiation treatment. The miR-196a mimic suppresses while its inhibitor promotes the resistance of NPC to radiation treatment. Importantly, the expression of p-IKKαT23 is positively related to the expression of miR-196a in human NPC tissues, and expression of p-IKKαT23 and miR-196a is inversely correlated with NPC clinical radioresistance. Thus, our studies establish a novel mechanistic link between the inactivation of IKKαT23–Drosha–miR-196a pathway and NPC radioresistance, and de-inactivation of IKKαT23–Drosha–miR-196a pathway would be an efficient way to restore the sensitivity of radioresistant NPC to radiotherapy.
Cell Death and Differentiation advance online publication, 8 April 2016; doi:10.1038/cdd.2016.32

Nasopharyngeal carcinoma (NPC) is one of the most common lethal malignancies diagnosed in Southeast Asia and southern China, where its incidence rate is approximately 25–50 cases per 100 000 population.[1] About 90% of NPC are undifferentiated carcinoma. Radiation therapy is the primary treatment for undifferentiated NPC. Although some NPCs are sensitive to radiotherapy, some are *de novo* or develop resistance to radiotherapy. It has been reported that approximately 30% of patients presenting localized tumors develop recurrent disease, and 30–60% of patients with metastatic NPC die within 5 years of diagnosis.[2,3] The mechanisms that cause NPC radiotherapy resistance are elusive.[4]

IKKα is a subunit of IκB kinase (IKK) complex that consists of two highly homologous kinase subunits (IKKα and IKKβ) and a nonenzymatic regulatory component, IKKγ/NEMO.[5] Nuclear factor-κB (NF-κB) is generally activated through IKK-dependent phosphorylation and subsequent degradation of IκB inhibitory proteins.[6] Liberated NF-κB dimers then enter the nucleus where they induce the transcription of various genes.[7,8] There are two NF-κB activation pathways: the classical pathway[6,9] and the alternative pathway.[10–12] IKKα contributes to the control of both pathways and functions in the cytoplasm. Recently, we found that IKKα can be translocated into the nucleus and nuclear IKKα plays important roles in prostate cancer progression and metastasis.[13,14]

MicroRNAs (miRNAs) regulate gene expression through suppression of translation and decay of target mRNAs, and are involved in diverse physiological and pathological processes. The primary transcripts of miRNA (pri-miRNA) are cleaved into precursor miRNA (pre-miRNA) by nuclear Drosha, and further processed to mature miRNAs by cytoplasmic Dicer1 in mammalian miRNA biogenesis. The Drosha complex consists of Drosha, DGCR8 (DiGeorge syndrome critical region gene 8), DDX5 (RNA helicase p68) and DDX17 (RNA helicase p72).[15] Recently, it has been reported that Smads, p53 and breast cancer 1 (BRCA1) are involved in miRNA maturation.[16–18]

Here, we examined the role of IKKα in cancer radiotherapy resistance, and found that IKKα-mediated biogenesis of miR-196a via interaction with Drosha regulates the sensitivity of NPC cells to radiation treatment.

Results

IKKα is dephosphorylated at T23 site in radioresistant NPC cells. To investigate the mechanisms that cause NPC

[1]Xiangya Hospital, Central South University, Hunan 410008, China; [2]Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL 33458, USA; [3]Department of Anatomical & Cellular Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; [4]Department of Anatomy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; [5]Department of Molecular Virology, Immunology, and Medical Genetics, Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA and [6]School of Life Sciences, Central South University, Hunan 410008, China
*Corresponding author: J-L Luo or X Feng or Y Tian, Xiangya Hospital, Central South University, or Department of Cancer Biology, The Scripps Research Institute, Florida Campus, USA, 130 Scripps Way, Jupiter, FL 33458, USA. Tel: +1 561 2283202; E-mail: jlluo@scripps.edu or fxp1029@aliyun.cn or yongquantian2013@163.com
Abbreviations: ATM, ataxia telangiectasia-mutated protein kinase; BRCA1, Breast cancer susceptibility gene 1; CHK2, Checkpoint kinase 2; DDX5, DEAD (Asp-Glu-Ala-Asp) box helicase 5; DDX17, DEAD-box helicase 17; DHX9, DEAH (Asp-Glu-Ala-His) Box Helicase 9; DGCR8, DiGeorge syndrome critical region gene 8; EMSA, electrophoretic mobility shift assay; hnRNP A1, heterogeneous nuclear ribonucleoprotein A1; IKK, IκB kinase; IR, ionizing radiation; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NPC, nasopharyngeal carcinoma; PI3K, phosphoinositide 3-kinase; RIP, RNA immunoprecipitation; Smad, Sma and Mad
Received 14.7.15; revised 22.2.16; accepted 29.2.16; Edited by V Stambolic

radioresistance, we established several radioresistant NPC cell lines (Figure 1a) via two different approaches. The radioresistant C666-S8GY cells were obtained from the colonies survived from those C666-1 NPC cells treated with a single high dosage of radiation (8 Gy). The radioresistant C666-M2GY cells were from those survived C666-1 NPC cells treated with radiation 2 Gy a day, 5 days a week for four consecutive weeks. To confirm the radioresistance of these cell lines, C666-S8GY, C666-M2GY and control C666-1 cells were treated with 6 Gy radiation, and cell viability, soft agar colony formation and tumor sphere formation were determined. We found that both C666-S8GY and C666-M2GY



cells were highly resistant to radiation treatment (Figure 1b). In addition, the irradiated C666-S8GY and C666-M2GY cells formed much more colonies in soft agar and had much bigger tumor spheres in suspension culture than irradiated control C666-1 cells (Figures 1c and d).

It has been reported that IKK*a* plays a role in NPC development.[19,20] To examine whether IKK*a* is activated in radioresistant NPC cells, the phosphorylation levels of IKK*a* at S176/S180 and T23 sites were detected by western blot. Surprisingly, we found that the expression level of p-IKK*a*T23 in both C666-S8GY and C666-M2GY cells was significantly decreased while the phosphorylation of IKK*a* at S176/S180 sites was unchanged as compared with C666-1 control cells (Figure 1e). Using the same strategy as for C666-1 cell, we established radioresistant HONE1 cells. Similarly, we found that the expression level of p-IKK*a*T23 in radioresistant HONE1 cells was significantly decreased while the phosphorylation of IKK*a* at S176/S180 sites was unchanged as compared with HONE1 control cells. These results indicate that IKK*a* is dephosphorylated at T23 site in radioresistant NPC cells.

The dephosphorylation of p-IKK*a*T23 promotes NPC cell radioresistance. To investigate whether the phosphorylation of IKK*a*T23 is related to the sensitivity of NPC cells to radiation, we established an IKK*a* stable knocked-down cell line (C666-IKK*a*-KD) by infecting C666-1 cells with IKK*a* shRNA lentivirus that specifically target 3′-UTR of IKK*a*. C666-IKK*a*-KD cells were used to express exogenous IKK*a* as IKK*a* shRNA does not interfere with open reading frames expression of IKK*a*. We established stable cell lines by transfecting C666-IKK*a*-KD cells with plasmid expressing HA-tagged wild type or a mutant IKK*a* where the 23rd amino acid threonine was replaced by alanine through mutagenesis. These cell lines were named C666-IKK*a*-23A cells and C666-IKK*a*-23T cells, and expressed similar amounts of exogenous IKK*a* protein to the endogenous IKK*a* protein of C666-1 control cells (Figure 1f). MTT assay showed that C666-IKK*a*-23A cells were more resistant to radiation than C666-IKK*a*-23T cells (Figure 1g). C666-IKK*a*-23A cells pretreated with 6 Gy of radiation had more colony formation in soft agar and formed more and bigger tumor spheres in suspension culture than C666-IKK*a*-23T cells pretreated with the same dosage of radiation (Figures 1h and i). Furthermore, we found that C666-IKK*a*-23A cells pretreated with 6 Gy of radiation developed xenograft tumors in Rag1$^{-/-}$ mice considerably more rapidly than the preirradiated C666-IKK*a*-23T cells (Figures 1j and k). These results suggest that the dephosphorylation of p-IKK*a*T23 promotes NPC cells resistance to radiation treatment.

IKK*a*T23 regulates precursor and mature miRNA expression. In a campaign for the role of IKK*a* in prostate cancer development by microarray and quantitative RT-PCR(qRT-PCR), we found that a set of precursor and mature miRNAs, including miR-196a, miR-494 and miR-615, was downregulated whereas their primary transcripts were unchanged in IKK*a* knocked-down Myc-CaP cells (Figure 2a). We confirmed that the downregulation of these precursor and mature miRNAs was also shown in C666-IKK*a*-KD cells (Figure 2b). Furthermore, we found that these precursor and mature miRNAs were also decreased in C666-IKK*a*-23A as compared with C666-IKK*a*-23T cells (Figure 2c), suggesting that the regulation of IKK*a* on the precursor and mature miR-196a, miR-494 and miR-615 is related to the phosphorylation status of IKK*a*T23. Supporting this, the precursor and mature miR-196a, miR-494 and miR-615 were upregulated in another NPC cell line HONE1, while their expression levels were very low in NP69, a immortalized normal nasopharyngeal epithelial cell line in which IKK*a*T23 was not phosphorylated (Supplementary Figure S1). Importantly, these precursor and mature miRNAs were also downregulated in C666-S8GY, C666-M2GY and radioresitant HONE1 cells, among them miR-196a was the most decreased one in radioresistant NPC cells (Figure 2d). Therefore, in the following studies we focused on the characterization and the role of miR-196a in IKK*a*23 T-associated radioresistance.

IKK*a*T23 mediates pri-miR-196a processing via interaction with drosha complex. The precursor and mature miR-196a were downregulated whereas its primary transcripts were unchanged in IKK*a* knocked-down cells, suggesting that IKK*a* may regulate miRNA biogenesis at the precursor level. As Drosha controls the biogenesis of miRNA precursors, the requirement of IKK*a* for miR-196a processing could be via its interaction with the Drosha microprocessor complex. To determine whether IKK*a* interacts with Drosha, we did co-immunoprecipitation between endogenous IKK*a* and Drosha in both C666-1 and Myc-CaP cells, and found that IKK*a* and Drosha could be reciprocally co-immunoprecipitated in both cells (Figure 3a and Supplementary Figure S2). We also did co-immunoprecipitation with anti-HA antibody in C666-IKK*a*-23T and C666-IKK*a*-23A cells, and found that HA-IKK*a*23 T could pull down Drosha while HA-IKK*a*23 A could not co-immunoprecipitate Drosha (Figure 3b), suggesting the phosphorylation status of IKK*a* at T23 is associated

Figure 1 The KKαT23 phosphorylation status is related to the sensitivity of NPC cells to radiation treatment. (**a**) Establish radioresistant cell lines (C666-S8GY and C666-M2GY cells) using two different approaches. Scale bars represent 100 μm. (**b**) MTT assay shows cell viability of C666-S8GY, C666-M2GY and control C666-1 cells after radiation treatment. (**c**) Soft agar colony formation of C666-S8GY, C666-M2GY and control C666-1 cells after 6 Gy radiation treatment. (**d**) Tumor sphere formation of C666-S8GY, C666-M2GY and control C666-1 cells after 6 Gy radiation treatment. Scale bars represent 100 μm. (**e**) Western blot analysis for the expression of p-IKKαT23 and p-IKKαS176/S180 in indicated NPC cell lines. (**f**) Western blot analysis for the expression of IKKα in C666-IKKα-23A (IKKα23A), C666-IKKα-23T (IKKα23T), C666-IKKα-KD (IKKα-sh) and control C666-1 (Con-sh) cell lines. (**g**) MTT assay shows cell viability of C666-IKKα-23A and C666-IKKα-23T cells after different dosages of radiation treatment. (**h**) Soft agar colony formation of C666-IKKα-23A and C666-IKKα-23T cells after 6 Gy radiation treatment. (**i**) Tumor spheres formation of C666-IKKα-23A and C666-IKKα-23T cells after 6 Gy of radiation treatment. Scale bars represent 100 μm. (**j**) Tumorigenecity analysis in Rag1$^{-/-}$ mice inoculated with C666-IKKα-23T (IKKα23T) or C666-IKKα-23A (IKKα23A) cells pretreated with 6 Gy of radiation treatment. (**k**) Comparison of the weight of tumors derived from irradiated C666-IKKα-23T (IKKα23T) and C666-IKKα-23A (IKKα23A) cells inoculated in Rag1$^{-/-}$ mice for 30 days. Note: $^{**}P<0.01$



Figure 2 IKKαT23 regulates the expression of pre- and mature miRNAs. (**a**) Expression levels of the primary (pri), precursor (pre) and mature forms of the indicated miRNAs were examined in IKKα knockout and control Myc-CaP prostate cancer cells using qRT-PCR analysis. (**b**) Expression levels of the primary (pri), precursor (pre) and mature forms of the indicated miRNAs were examined in C666-IKKα-KD and control C666-1 NPC cells using qRT-PCR analysis. (**c**) Expression levels of the primary (pri), precursor (pre) and mature (mat) forms of the indicated miRNAs were examined in C666-IKKα-23A (IKKα23A) and C666-IKKα-23T (IKKα23T) cells using qRT-PCR analysis. (**d**) Expression levels of the primary (pri), precursor (pre) and mature forms of the indicated miRNAs were examined in C666-S8GY, C666-M2GY and control C666-1 cells using qRT-PCR analysis. Note: Pri- and pre-miRNAs were normalized by GAPDH, and mature miRNA was normalized by U6 snRNA (*$P<0.05$; **$P<0.01$; $n=3$)

with the interaction between IKK*a* and Drosha. Supporting this hypothesis, IKK*a* and Drosha could be reciprocally co-immunoprecipitated in C666-1 cells, while the IKK*a* antibody could not or co-immunoprecipitated much lower level of Drosha in both radioresistant NPC cell lines, C666-S8GY and C666-M2GY, in which IKK*a* was dephosphorylated at T23 site (Figure 3c). Together, these results suggest that phosphorylation of IKK*a*23 T promotes the binding of IKK*a* protein to the Drosha complex.

To determine whether IKK*a* processes pri-miR-196a substrate, we performed an *in vitro* pri-miRNA processing assay by incubating FITC-labeled pri-let-7b, pri-miR-196a1 and pri-miR-196a2 substrates with immunoprecipitated IKK*a* complex from C666-IKK*a*-23T and C666-IKK*a*-23A cells. Immunoprecipitated IKK*a* complex from C666-IKK*a*-23T cells potentiated the processing of pri-miR-196a1, pri-miR-196a2, but not pri-let-7b, whereas immunoprecipitated IKK*a* complex from C666-IKK*a*-23A cells did not potentiate the processing of pri-miR-196a1, pri-miR-196a2 and pri-let-7b (Figure 3d), indicating that immunoprecipitated IKK*a*-23T complex has pri-miRNA processing activity while the IKK*a*-23A complex lost this function. Supporting this hypothesis, immunoprecipitated IKK*a* complex from C666-1 cells potentiated the processing of pri-miR-196a1 and pri-miR-196a2, while immunoprecipitated IKK*a* complex from C666-S8GY and C666-M2GY cells, where IKK*a*-T23 was dephosphorylated, did not potentiate the processing of pri-miR-196a1 and pri-miR-196a2 (Figure 3e).



Figure 3 IKKα mediates pri-miR-196a processing by interacting with the Drosha complex. (**a**) C666-1 NPC cells were immunoprecipitated (IP) with anti-IKKα or anti-Drosha, followed by immunostaining with anti-IKKα or anti-Drosha antibody. (**b**) C666-IKKα-23A and C666-IKKα-23T cells were IP with anti-HA, followed by immunostaining with the anti-Drosha antibody or anti-HA antibody. (**c**) C666-S8GY cells (S8GY), C666-M2GY cells (M2GY) and control C666-1 cells were IP with anti-IKKα, followed by immunostaining with the anti-Drosha antibody. (**d**) *In vitro* pri-miRNA processing assays of pri-miR-196a1, pri-miR-196a2 with IKKα or Drosha complex immunoprecipitated from C666-IKKα-23A and C666-IKKα-23T cells. (**e**) *In vitro* pri-miRNA processing assays of pri-miR-196a1 and pri-miR-196a2 with immunoprecipitated IKKα or Drosha complex from C666-S8GY, C666-M2GY and control C666-1 cells. (**f**) *In vivo* monitoring assay of pri-miRNA processing in C666-IKKα-KD and C666-1 control cells carrying pri-miR-196a1 and pri-miR-196a2 at the 3′ untranslated region of the luciferase gene. The intensities were normalized by renilla luciferase and are shown as fold induction as compared with an empty vector (**$P<0.01$; $n=3$). (**g**) *In vivo* monitoring assay of pri-miRNA processing in C666-S8GY, C666-M2GY and control C666-1 cells carrying pri-miR-196a1 and pri-miR-196a2 at the 3′ untranslated region of the luciferase gene. The intensities were normalized by renilla luciferase and are shown as fold induction as compared with an empty vector

Furthermore, we also conducted an *in vivo* cellular monitoring assay. C666-IKK*α*-23T and C666-IKK*α*-23A cells were transfected with a luciferase construct carrying a segment of pri-miR-196a1, pri-miR-196a2 or pri-let-7b between the luciferase gene and the polyadenylation signal. If luciferase transcripts lose their polyadenylation tail due to the cleavage of pri-miRNAs, its stability and translation efficiency will be significantly decreased. Consistent with the *in vitro* results, we found that the luciferase activity in C666-IKK*α*-23T cells transfected with luciferase construct carrying a segment of miR-196a1, pri-miR-196a2 in 3′-UTR was significantly decreased, while it was unchanged in C666-IKK*α*-23A cells (Figure 3f). In addition, we found that that the luciferase activity in C666-1 control cells transfected with luciferase construct carrying a segment of miR-196a1, pri-miR-196a2, in 3′-UTR was significantly decreased, while it was unchanged in C666-S8GY and C666-M2GY cells where IKK*α*T23 was dephosphorylated (Figure 3g). Collectively, these results demonstrate that the phosphorylation status of IKK*α* at T23 site is important for the binding of IKK*α* protein to the Drosha complex and consequently for the processing of primary miR-196a.

IKK*α* binds to primary miR-196a. Our studies showed IKK*α*T23 only regulated the processing of a group of miRNAs (Figure 2). To investigate why IKK*α*T23 specifically processes the biogenesis of primary miR-196a a co-immunoprecipitation between endogenous IKK*α* and Drosha in C666-1 cells was performed, followed by addition of RNase A. We found that the association of IKK*α* with Drosha was markedly decreased by treatment with RNase A, indicating that IKK*α* interacts with the Drosha complex via RNA



Figure 4 IKKαT23 phosphorylation status determines its association with pri-miR196a. (**a**) RNA dependence of interactions of IKKα with Drosha. Immunoprecipitates were treated with RNase A and subjected to immunoblot analysis. (**b**) RIP analysis of the association between IKKα and pri-let7b, pri-miR-196a1, pri-miR-196a2 in C666-IKKα-23A and C666-IKKα-23T cells. Cells were immunoprecipitated with the anti-HA, and subjected to qRT-PCR analysis with pri-let7b, miR-196a1 and miR-196a2 primers (**$P<0.01$; $n=3$). (**c**) RIP analysis of the association between IKKα and pri-let7b, pri-miR-196a1, pri-miR-196a2 in C666-S8GY, C666-M2GY and control C666-1 cells. Cells were immunoprecipitated with the anti-IKKα or anti-Drosha, and subjected to qRT-PCR analysis with pri-let7b, miR-196a1 and miR-196a2 primers. As a control, an RNA sample was immunoprecipitated with nonspecific mouse IgG (mIgG) or rabbit IgG (rIgG) and subjected to qPCR (**$P<0.01$; $n=3$). (**d**) EMSA was performed with FITC-labeled pri-let7b, pri-miR-196a1 and pri-miR-196a2 probes and *in vitro* translated IKKα23 A and IKKα23 T proteins. Shifted bands as a result of specific binding to IKKα are shown. 'Free' indicates an unbound probe. The experiment was performed three times and a representative blot is shown

molecules (Figure 4a). To examine whether IKK*α* engages with pri-miR-196a *in vivo*, RNA immunoprecipitation (RIP) analysis was performed in both C666-IKK*α*-23T and C666-IKK*α*-23A cells. We found that HA-IKK*α* pulled down pri-miR-196a1 and miR-196a2, but not pri-let7b in C666-IKK*α*-23T cells, while HA-IKK*α* did not precipitate pri-miR-196a1 and miR-196a2, and pri-let7b in C666-IKK*α*-23A cells. These results suggest that the phosphorylation status of IKK*α*23 T is important for the association of IKK*α* with pri-miR-196a1 and pri-miR-196a2 (Figure 4b). Consistently, anti-IKK*α* antibody could immunoprecipitate pri-miR-196a1 and pri-miR-196a2 in C666-1 cells, whereas it could not co-immunoprecipitate these primary miRNAs in both C666-S8GY and C666-M2GY NPC cell lines, in which IKK*α*T23 was dephosphorylated (Figure 4c).

To further confirm the interaction of IKK*α* with pri-miR-196a, an electrophoretic mobility shift assay (EMSA) was performed using *in vitro* translated functional full-length IKK*α* protein and FITC-labeled pri-miR-196a1, pri-miR-196a2 and pri-let7b as probes. Consistent with the results of the RIP assay, bands for pri-miR-196a1 and pri-miR-196a2, but not pri-let7b were shifted with the IKK*α*-23T but not IKK*α*-23A protein, and bands for pri-let7b were not shifted with either IKK*α*-23T or IKK*α*-23A protein (Figure 4d), suggesting that the specific binding of IKK*α* to pri-miR-196a1 and pri-miR-196a2 is dependent on the status of IKK*α*T23. Together, these results indicate that the specific binding of p-IKK*α*T23 to pri-miR-196a leads to explicit participation of p-IKK*α*T23 in the biogenesis of miR-196a.

IKK*α* phosphorylates Drosha. To investigate whether IKK*α* affects the function of Drosha, we compared the expression and localization of Drosha between IKK*α* knockdown and control NPC cells. As Drosha is a nuclear protein, C666-1 cells had a strong nuclear Drosha staining; however, in addition to an intense nuclear Drosha staining IKK*α* knockdown cells also showed a diffused cytoplasmic staining of Drosha (Figures 5a and b). We also performed immunofluorescence of Drosha in C666-IKK*α*-23T and C666-IKK*α*-23A cells. Interestingly, C666-IKK*α*-23T cells had a unique and strong nuclear Drosha staining while C666-IKK*α*-23A cells showed both nuclear and cytoplasmic staining of Drosha, suggesting that the phosphorylation status of IKK*α*T23 is associated with the localization of Drosha (Figure 5c). Supporting this phenomenon, Drosha was uniquely stained in nucleus of control C666-1 cells while it was stained in both nucleus and cytoplasm of radioresistant C666-S8GY and C666-M2GY NPC cells, in which IKK*α* was dephosphorylated at T23 site (Figure 5d).

It has been reported that the phosphorylation of Drosha is essential for it nuclear localization.[21] The diffuse staining of Drosha in the cytoplasm of IKK*α* knockdown cells suggests that IKK*α* may phosphorylate Drosha. To verify this hypothesis we performed an *in vitro* kinase assay using an active IKK*α* protein and a recombinant Drosha protein, and we found that IKK*α* phosphorylated Drosha *in vitro* (Figure 5e). Together, these results suggest that phosphorylation of IKK*α* at 23 T site promotes the association of IKK*α* with a group of pri-miRNAs, including miR-196a, where IKK*α* phosphorylates Drosha, leading to increased processing of these miRNAs (Figure 5f).

IKK*α*T23-mediated miR-196a biogenesis regulates the sensitivity of NPC cells to radiation. As miR-196a was downregulated in radioresistant NPC cells, its expression may be related to the sensitivity of NPC cells to radiation treatment. To test this hypothesis, both C666-S8GY and C666-M2GY cells were incubated with miR-196a mimics, followed by treatment with radiation. We found that miR-196a mimics restored the sensitivity of C666-S8GY and C666-M2GY to radiation treatment (Figure 6a), suggesting that miR-196a is a key regulator of NPC cells' response to radiation treatment.



Figure 5 IKKα phosphorylates Drosha. (**a**) Endogenous Drosha staining in C666-IKKα-KD and control C666-1 NPC cells (×400). Scale bars represent 50 μm. (**b**) Endogenous Drosha staining in IKKα knockdown and control Myc-CaP cells (×400). Scale bars represent 50 μm. (**c**) Endogenous Drosha staining in C666-IKKα-23A and C666-IKKα-23T cells (×400). Scale bars represent 50 μm. (**d**) Endogenous Drosha staining in C666-S8GY cells and control C666-1 cells (×400). Scale bars represent 50 μm. (**e**) *In vitro* phosphorylation of Drosha by an active IKKα protein in the presence of 5 μCi [γ-^{32}P]-ATP and 200 μM cold ATP. The reaction was resolved on SDS-PAGE, and the phosphorylation of Drosha was detected by autoradiography. Coomassie blue staining of the SDS-PAGE gel was also shown for loading control. (**f**) IKKα regulates miRNA biogenesis. IKKα recognizes pri-miRNA, associates with the Drosha microprocessor, phosphorylates Drosha and enhances miRNA processing

To further investigate the role of miR-196a in p-IKKα23 T-mediated regulation of NPC cells' response to radiation treatment, C666-IKKα-23T cells that had high levels of endogenous miR-196a were incubated with miR-196a inhibitors or vehicle while C666-IKKα-23A cells that had a low level of endogenous miR-196a were incubated with miR-196a mimics or vehicle. After 12 h, these cells were treated by radiation and subjected to MTT, soft agar colony formation and tumor sphere formation assays. We found that C666-IKKα-23T cells incubated with miR-196a inhibitors were significantly more resistant to radiation treatment (Figure 6b), and formed more colonies in soft agar (Figure 6c) and more tumor spheres in suspension culture (Figure 6d) than the cells incubated with vehicle. In contrast, C666-IKKα-23A cells incubated with miR-196a mimics were considerably more sensitive to radiation treatment, and had less cell viability (Figure 6e) and less colonies in soft agar (Figure 6f), and formed less and smaller tumor spheres in suspension culture (Figure 6g) than the cells incubated with vehicle. These results suggest that overexpression of miR-196a sensitizes NPC cells to radiation treatment while downregulation of miR-196a protects cells from radiation-induced cell death.

IKKαT23-mediated regulation of miR-196a is associated with the radioresistance of clinical human NPC. To investigate the relevance of IKKαT23-mediated regulation of miR-196a to radiotherapy resistance of clinical human NPC, we examined the expression of p-IKKαT23 and miR-196a by immunohistochemistry and *in situ* hybridization, respectively, in paraffin-embedded sections of 116 cases of NPC. Forty-seven cases of the NPC were radiotherapy resistance while 69 cases were radiotherapy sensitive. We found that most of radiosensitive NPC cases had strong p-IKKαT23 staining while most of radioresistant NPC cases had weak or moderate p-IKKαT23 expression. The expression levels of p-IKKαT23 in radiosensitive and radioresistant NPC tissues were significantly different (Figures 7a and b). Similarly, miR-196a was strongly expressed in most of the radiosensitive NPC tissues while the expression of miR-196a in most of radioresistant NPC tissues was weak or moderate. The expression levels of miR-196a in radiosensitive and



Figure 6 IKKαT23-mediated regulation on pri-miR-196a processing plays important roles in NPC radioresistance. (**a**) MTT assay shows cell viability of C666-S8GY and C666-M2GY cells incubated with miR-196a mimics, followed by 6 Gy of radiation treatment. (**b**) MTT assay shows cell viability of C666-IKKα-23T cells incubated with miR-196a inhibitors, followed by 6 Gy of radiation treatment. (**c**) Soft agar colony formation of C666-IKKα-23T cells incubated with miR-196a inhibitors, followed by 6 Gy of radiation treatment. (**d**) Tumor spheres formation of C666-IKKα-23T cells incubated with miR-196a inhibitors, followed by 6 Gy of radiation treatment. Scale bars represent 100 μm. (**e**) MTT assay shows cell viability of C666-IKKα-23A cells incubated with miR-196a mimics, followed by 6 Gy of radiation treatment. (**f**) Soft agar colony formation of C666-IKKα-23A cells incubated with miR-196a mimics, followed by 6 Gy of radiation treatment. (**g**) Tumor spheres formation of C666-IKKα-23A cells incubated with miR-196a mimics, followed by 6 Gy of radiation treatment. Scale bars represent 100 μm. Note: $^{**}P < 0.01$

radioresistant NPC tissues were significantly different (Figures 7c and d). Furthermore, the expression of p-IKKαT23 was positively correlated with the expression of miR-196a in human NPC tissues (Figure 7e).

Discussion

Radiotherapy is the most commonly applied treatment for undifferentiated NPC, but tumor recurrence is essentially universal due to marked radioresistance.[2,3] Ionizing radiation (IR) causes damage to cellular structures of irradiated cells, including DNA. IR induces DNA damage either by directly damaging the DNA or by indirectly generating reactive oxygen species, which ultimately alter the chemical structure of DNA, leading tumor cells to halting cellular proliferation and initiating a DNA damage response. With extensive DNA damage, a cell usually undergoes cell death, which is the mechanism by which radiation functions therapeutically to reduce tumor burden. However, tumor cells often possess or acquire radioprotective capabilities that enable them to escape radiation-induced cell death. Several signaling pathways, including PI3K/AKT, mitogen-activated protein kinase and



Figure 7 IKKαT23-mediated regulation of miR-196a is related to radioresistance of human NPC. (**a**) IHC of p-IKKαT23 (×400). (**b**) Correlation between p-IKKαT23 expression and human NPC radioresistance. (**c**) ISH of miR-196a (×400). (**d**) Correlation between miR-196a expression and human NPC radioresistance. (**e**) Correlation between p-IKKαT23 and miR-196a expression in human NPC tissues

ATM/CHK2/p53, have been linked to the tumor radioresistance.[22,23] In the present study we have demonstrated that IKKα-mediated miR-196a biogenesis regulates the sensitivity of NPC cells to radiotherapy. Dephosphorylation of p-IKKαT23 downregulates miR-196a expression and promotes the resistance of NPC cells to radiation treatment.

The biogenesis of mature miRNAs is a multistep process that starts with the initial transcription of their genes by RNA polymerase II, resulting in long, capped and polyadenylated primary miRNAs (pri-miRNA). The pri-miRNA are processed in the nucleus by the Drosha complex, releasing a ~65–70 nucleotide hairpin structure precursor miRNA (pre-miRNA). The pre-miRNA is then exported to the cytoplasm and cleaved by Dicer into double stranded miRNAs.[24–26]

It has been reported that Drosha associates with dozens of distinct polypeptides, including DGCR8, to form a large 'microprocessor' Drosha complex.[27] The processing of pri-miRNA by the Drosha complex takes place concurrently with or shortly after transcription.[28] DGCR8, which can directly interact with pri-miRNA, assists this process by correctly positioning Drosha on the pri-miRNA.[29] Other proteins, including Lin28, nuclear ribonucleoprotein (hnRNP) A1, R-Smads, p53 and BRCA1, interact with Drosha and specifically regulate the processing of a group of pri-miRNA. Lin28 and hnRNP A1 interact with Drosha by binding to the terminal loop region of pri-let-7 and pri-miR-18a, respectively.[30,31] The signal transducers of the transforming growth factor β/bone morphogenetic protein, the Smads, promote the expression of a subset of miRNAs, including miR-21 and miR-199a, by facilitating the cleavage reaction by Drosha.[16,32] In response to DNA damage, p53 interacts with the Drosha processing complex through its association with DEAD-box RNA helicase p68 (also known as DDX5) and facilitates the processing of primary miRNAs to precursor miRNAs, which enhances the post-transcriptional maturation of several miRNAs with growth-suppressive function, including miR-16-1, miR-143 and miR-145.[18] Tumor suppressor BRCA1 regulates the biogenesis of a group of miRNA biogenesis, including let-7a-1, miR-16-1, miR-145 and miR-34a, via direct association with the Drosha microprocessor complex and Smad3/p53/DHX9.[17]

In this study, we identified a set of miRNAs that is regulated post-transcriptionally by IKKα. IKKα is a component of the IKK complex.[5] In addition to its cytoplasmic functions where it controls the activation of both classical and alternative NF-κB pathways,[6,9–12] IKKα can function as a nuclear protein kinase,[33–35] and nuclear IKKα plays important roles in prostate cancer progression and metastasis.[13,14] In the present study we have shown that IKKα controls the biogenesis of a group of miRNA, including miR-196a. Phosphorylation of IKKα at 23 T site promotes the association of IKKα with pri-miRNAs, where

IKKα phosphorylates Drosha, leading to increased biogenesis of these miRNAs.

MiR-196a has two forms: miR-196a1 and miR-196a2. Although miR-196a1 and miR-196a2 are transcribed from two different genes, the mature nucleotide sequences of miR-196a1 (Promega, Madison, WI, USA) and miR-196a2 are identical. It has been reported that miR-196a plays important role in development, immunity, cancer and cell differentiation.[36] However, the detailed functions and molecular mechanisms by which miR-196a contributes to these physiological and pathological process remain largely unknown.[36] Particularly, the roles of miR-196a in cancer are elusive. Some reports suggest that miR-196a plays an oncogenic role in tumor development,[37,38] while others indicate that miR-196a may be a tumor suppressor. For instance, it was reported that the expression of miR-196a was dramatically decreased in melanoma cells when compared with healthy control melanocytes, and the low miR-196a expression in melanoma cells enhanced migratory potential of these melanoma cells.[39] Moreover, enforced expression of miR-196a reduced *in vitro* invasion and *in vivo* spontaneous metastasis of breast cancer cells.[40] In addition, overexpression of miR-196a inhibited the proliferation of human adipose tissue-derived mesenchymal stem cells while enhancing osteogenic differentiation.[41] Our results show that NPC cells become radioresistant by reducing the expression of miR--196a, and expression of miR-196a restores the sensitivity of radioresistant NPC to radiation therapy. Importantly, the expression level of miR-196a in clinical NPC samples is correlated with the sensitivity of NPC to radiotherapy. Our study suggests that miR-196a is a good clinical biomarker for predicting the sensitivity of NPC to radiotherapy and miR-196a is a potential radiosensitizer for NPC radiotherapy.

Materials and Methods

Cell cultures. The human NPC cell lines C666-1,[42] HONE1[43] and the mouse prostate cancer cell line Myc-CaP were cultured in RPMI-1640 medium (Lonza, Walkersville, MD, USA) supplement with 10% fetal bovine serum (Atlanta Biological, Flowery Branch, GA, USA) and 1% penicillin–streptomycin solution (Thermo scientific, Waltham, MA, USA). The immortalized normal nasopharyngeal epithelial cell line NP69[44] were cultured and grown in defined keratinocyte-SFM (Life Technologies, Carlsbad, CA, USA) with growth supplement and bovine pituitary extract (Sigma-Aldrich, St. Louis, MO, USA) and penicillin–streptomycin. Cells were cultured at 37 °C with 5% CO_2 in an incubator.

Antibodies. The following antibodies were used: IKKα antibody (Novus Biological, Littleton, CO, USA; #NBP2-27409), phospho-IKKα antibody (Thr23; Sigma-Aldrich; #SAB4300106), phospho-IKKα antibody (Ser176/180; Cell Signaling; #2697S), Drosha antibody (Cell Signaling; #3364S), HA antibody (Roche, Indianapolis, IN, USA; #11867423001), normal mouse IgG (Santa Cruz; #sc-2025), normal rabbit IgG (Santa Cruz; #sc-2027), β-actin antibody (Santa Cruz; #sc-47778), HRP-linked anti-mouse IgG (GenScript, Piscataway, NJ, USA; #A00160), HRP-linked anti–rabbit IgG (Santa Cruz; #sc-2004), FITC conjugated anti-mouse IgG (Sigma).

Cell irradiation and the establishment of radioresistant NPC cells. Two approaches were employed to establish radioresistant NPC cell lines. Approach 1: NPC C666-1 and HONE1 cells were seeded at a density of 1.5×10^6 per well in a six-well plate and cultured overnight. Cells were irradiated at the dosage of 2 Gy per day for consecutive five days per week for 4 weeks to establish radioresistant NPC cells, named as C666-1-M2GY and NONE1-M2GY. Approach 2: C666-1 and HONE1 cells at a density of 2×10^5 per well in a 24-well plate were given a sublethal does of 8 Gy, and 48 h later cells were dissociated into single cells and seeded in 15 cm dish. Three weeks later large colonies were picked and examined for the radiation resistance. These colonies were named C666-1-S8GY and HONE1-S8GY. MTT, soft agar colony formation and tumor sphere formation assay were performed to assess the radioresistance of these cells.

MTT assay. Cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) (Life Technologies) colorimetric assay. Briefly cells were seeded in 96-well plates at a density of $10 \times ^3$ cells per well, after 6 days incubation, MTT solution (Life Technologies) was added to wells and incubated for 4 h in 37 °C. The absorbance was measured at 570/630 nm using a spectrophotometer (SpectraMax M5; Molecular Devices Corp, Sunnyvale, CA, USA).

Soft agar colony formation assay. To assess anchorage independent growth, 2000 cells were seeded in medium containing 0.35% agarose (LowMelt Agarose; GeneMate, Kaysville, UT, USA) on top of 0.7% agarose/media. After solidifying the cells were covered with media. Media was changed two times every week. Colonies were stained with 0.01% crystal violet (Alfa Aesar, Ward Hill, MA, USA) and examined after 25 days of culture. Colonies larger than 50 μM were enumerated.

Tumor sphere formation assay. For tumor sphere formation assay, cells were dissociated into single cells and seeded in low cell density (5×10^2) on a six-well ultra-low cluster plate (Sigma-Aldrich), and cultured with serum-free DMEM/F12 (Invitrogen, Carlsbad, CA, USA), 20 ng/ml EGF (Sigma-Aldrich), 20 ng/ml bFGF (Cell Signaling, Beverly, MA, USA) and 20 ng/ml insulin (Cell Signaling). The images of tumor spheres were captured under a microscope equipped with a camera at days 1, 7 and 15 of culture.

Western blot analysis. Cells were collected and lysed with ice-cold lysis buffer containing 0.25% protease inhibitor (Calbiochem, La Jolla, CA, USA) and phosphatase inhibitor (Roche). Samples were resolved on 8–15% SDS-polyacrylamide gel and transferred to PVDF membrane (Millipore, Billerica, MA, USA). The membrane was blocked with milk or 5% BSA (Fisher Scientific, Hanover Park, IL, USA), and incubated with primary antibodies, followed by incubation with corresponding secondary antibodies. An ECL western blotting substrate (Thermo Scientific) was added and chemiluminescence signal was detected.

Immunoprecipitation and immunoblot assays. For C666-1, HONE1 and Myc-CaP cells, 500 μg/400 μl cleared lysates were incubated with the anti-IKKα/DROSHA or control IgG antibodies, Protein A/G PLUS-Agarose Beads (Santa Cruz, Dallas, TX, USA) overnight at 4 °C. Beads were washed three times with stringent buffer, and then mixed with 20 μl of loading buffer and incubated at 95 °C for 5 min. After centrifugation, supernatants were subjected to SDS-PAGE and transferred to PVDF membrane. Immunoblotting was performed with the indicated antibodies. For C666-IKKα-23T and C666-IKKα-23A stable cell lines, Pierce Anti-HA Magnetic Beads (Thermo Scientific) were used according to the manufacturer's instructions.

qRT-PCR assays. qRT-PCR assays were performed to determine the expression levels of primary, precursor and mature miRNAs. Briefly, total RNA was purified using RNeasy Mini Kit (Qiagen, Valencia, CA, USA), and then reverse transcribed with High-Capacity Reverse Transcription Kit (Applied Biosystems by Life Technologies). Mature miRNA was prepare using mirVana miRNA Isolation Kit (Ambion by Life Technologies), and then reverse transcription was carried out using Universal cDNA Synthesis Kit II (Exiqon, Woburn, MA, USA). The qPCR reaction was performed using a 5× Hot FIREPol EvaGreen qPCR SuperMix (Solis BioDyne, Tartu, Estonia), according to the manufacturer's instructions. Data analysis was performed using the comparative Ct method. Results were normalized to human 18S rRNA for pri- and pre-miRNAs, or human 5S rRNA for mature miRNAs. The primer sequences used are shown in Supplementary Table S1.

Xenograft mouse model. Six-week-old Rag1$^{-/-}$ mice were subcutaneously inoculated with 1×10^7 NPC cells with Matrigel Matrix (Corning, Tewksbury, MA, USA). Tumor formation was measured every 3 days for 30 days. The tumor volumes were calculated by the equation $V\ (mm^3) = a \times b^2/2$, where '*a*' is the largest diameter and '*b*' is the perpendicular diameter.

Transfections. We transfected cells with hsa-miR-196a Mimic (HMI0322; Sigma-Aldrich), hsa-miR-196a inhibitor (HSTUD0322; Sigma-Aldrich) and different kinds of plasmids using the TransIT-LT1 transfection reagent (Mirus, Madison, WI, USA),

according to manufacturer's recommendation. C666-IKKα-23T and C666-IKKα-23A stable cell lines were achieved by geneticin (Teknova, Hollister, CA, USA) selection. All transfection experiments were done in triplicates and repeated for three times.

shRNA lentivirus infection. C666-1 cells were infected with *lentivirus expressing IKKα* shRNA (Sigma-Aldrich) and empty vector with the LTV-201 (Cell Biolabs, Inc, San Diego, CA, USA). Cells were selected by puromycin. The efficiency of IKKα knockdown was determined by western blot.

***In vivo* monitoring of pri-miRNA processing.** Plasmid constructs with pri-miRNA (let7b, miR-196a1, miR-196a2) at the 3′ untranslated region of firefly luciferase cDNA and expression vectors were transfected into C666-1 cells. Cell extracts were prepared at 48 h after transfection, and the ratio of firefly and renilla luciferase was measured using a Dual-Luciferase Reporter Assay system (Promega). Values were further normalized by that of an empty vector and are indicated with standard deviation. The primer sequences used for cloning are shown in Supplementary Table S1.

***In vitro* pri-miRNA processing analysis.** Purified PCR products containing a T7 sequence and a 125-160 bp of pri-miR-196a1, pri-miR-196a2 and pri-let7b were transcribed *in vitro* (TranscriptAid T7 High Yield Transcription Kit; Thermo Scientific) and internally labeled with FITC (Fluorescein RNA Labeling Mix; Roche). Pri-miRNA was denatured for 5 min by heating at 65 °C and re-natured by gradually decreasing the temperature. At the same time, immunoprecipitated Drosha, immunoprecipitated IKKα complex from C666-1, immunoprecipitated HA-IKKα23 T and immunoprecipitated IKKα23 A complex from respective stable cell lines were prepared. Each processing reaction contained one of above-mentioned immunoprecipitated protein, FITC-labeled pri-miRNA, $MgCl_2$, ATP and RNase inhibitor. The reaction mixture was incubated at 37 °C for 120 min. After purification (RNeasy Mini Kit; Qiagen), RNA was loaded on 8% urea denaturing polyacrylamide gels, then analyzed using a E-Gel Imager (Life Technologies). The primer sequences used for PCR are shown in Supplementary Table S1.

RIP. All buffers used in RIP contained 0.5 U/μl RNase inhibitor (Applied Biosystems, Carlsbad, CA, USA). First, nuclei were isolated from 0.75% formaldehyde-fixed cells and chromatin was sheared using a homogenizer. After immunoprecipitation with anti-IKKα or anti-DROSHA or anti-HA antibodies, the precipitated RNA was isolated by using TRIzol RNA extraction reagent (Life Technologies). An aliquot of RNA was used for a cDNA synthesis reaction and qPCR analysis. The primer sequences used are shown in Supplementary Table S1.

EMSA. FITC-labeled pri-miR-196a1, pri-miR-196a2 and pri-let7b were prepared by using an *in vitro* transcription system as mentioned above. Recombinant IKKα23 T and IKKα23 A protein were synthesized by 1-Step Human High Yield *In Vitro* Translation Kits (Thermo Scientific). Denatured and re-natured pri-miRNA was mixed with recombinant protein at 4 °C for 1 h in EMSA buffer (10 mM Tris-HCl, pH 7.5, 150 mM KCl, 10% glycerol, 50 μg/ml poly[dI – dC] and RNase inhibitor). Bound complexes were resolved on 6% native polyacrylamide gels in 0.5 × Tris/borate/EDTA buffer and then analyzed using a E-Gel Imager (Life Technologies).

Tissues. Two hundred eighty-six NPC patients who were treated by curative-intent radiotherapy (a total dose of 60–70 Gy) using a modified linear accelerator in the Xiangya Hospital of Central South University, China from February 2004 to July 2013 were reviewed. All these NPC patients were followed-up after the first radiotherapy. Among these patients, 116 NPC patients without distant metastasis (M0; WHO staging II and III) at the time of diagnosis, comprising 47 radioresistant and 69 radiosensitive patients, were recruited in this study. Radioresistant NPC patients were defined as ones with persistent disease (incomplete regression of tumor) at >6 weeks after completion of radiotherapy or ones with recurrent disease at the nasopharynx and/or neck nodes at >2 months after completion of radiotherapy.[45,46] Radiosensitive NPC patients were defined as ones without the local residual lesions or recurrence 5 years after completion of radiotherapy. Diagnoses were established by experienced pathologists and NPC oncologist based on the 1978 WHO classification. The study was approved by the ethics committee of Xiangya School of Medicine, Central South University, China.

Immunohistochemistry. The expression of p-IKKαT23 in clinic NPC was performed on paraffin-embedded primary NPC tissue sections by immunohistochemical analysis. Briefly, 4-μm-thick tissue sections were treated with an antigen retrieval solution (10 mmol/l sodium citrate buffer (pH 6.0)), incubated (overnight, 4 °C) with anti-p-IKKαT23 antibody (1 : 300 dilution), then incubated with biotinylated secondary antibody (1 : 500 dilution), followed by avidin-biotin peroxidase complex (Dako, Carpinteria, CA, USA). Finally, tissue sections were stained with 3′,3′-diaminoben-zidine (Sigma) and counterstained with Harris' modified hematoxylin. In negative controls, primary antibodies were omitted.

All sections were examined and assessed independently by two investigators. A quantitative score was performed by adding the score of staining area and the score of staining intensity for each case to assess the protein expression levels as previously described.[47] At least 10 high-power fields were chosen randomly and >1000 cells were counted for each section. First, a quantitative score was performed by estimating the percentage of staining-positive cells: 0, no staining of cells in any microscopic field; 1+, $<30\%$ of cells stained positive; 2+, between 30 and 60% stained positive; and 3+, $>60\%$ stained positive. Second, the staining intensity score was evaluated as: 0, no staining; 1+, mild staining; 2+, moderate staining; 3+, intense staining. Finally a total score (ranging from 0 to 6) was obtained by adding the area score and the intensity score for each case. A combined staining score of $\leqslant 2$ was considered to be negative staining (no expression); a score between 3 and 4 was considered to be moderate staining (expression); and a score between 5 and 6 was considered to be strong staining (high expression).

***In situ* hybridization.** *In situ* hybridization was performed according to the manufacturer's protocol for formalin-fixed, paraffin-embedded tissue sections. The probes were 3′,5′-labeled with digoxigenin with the DIG tailing kit (Exiqon). After deparaffinization, the NPC tissue sections were subjected to proteinase K (40 μg/ml) digestion (10 min). The prehybridization (1 h) and hybridization (2 h) were subsequently treated by the manufacturer's instruction of the locked nucleic acid-modified probes. For the immuno detection, tissues were incubated overnight at 4 °C in anti–DIG-AP FAB fragment (1 : 1000). The final visualization was carried out with BCIP/NBTP. The stained sections were reviewed and scored under a light microscope (LEI CA DM5000 B, Buffalo Grove, IL, USA) independently by two investigators. The staining intensity score was evaluated as: 1 = no staining or weak staining, 2 = intermediate staining, 3 = strong staining; and the percentage of tissue cell staining was scored as: 0 = $<10\%$, 1 = 10–30%, 2 = 10–30%, 3 = $>60\%$). A combined staining score of $\leqslant 2$ was considered to be negative staining (no expression); a score between 3 and 4 was considered to be moderate staining (expression); and a score between 5 and 6 was considered to be strong staining (high expression).

Statistical analysis. Statistical analyses were performed using the statistical package SPSS 13.0 and Graphpad Prism 5. Difference of the protein expression between radiosensitive and radioresistant NPC tissues was analyzed using Student's *t*-test. The expression of p-IKKαT23 and miRNA-196α in NPC tissues was assessed for correlations. A two-sided $P<0.05$ was considered significant.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. We thank Dr. Xiaoli Tang and Dr. Bharat Ramratnam at Warren Alpert Medical School of Brown University for kindly providing us with GFP-Drosha plasmid. This work was supported by grants from the United States Department of Defense (W81XWH-09-1-0533) and National Institute of Health (1R01CA140956, 1R21NS073098) to J-LL, and China Nature Science Foundation (81472847, 81372905) to J-LL and XPF, by Scholarships from China Scholarship Council (CSC) to XPF and XL, and an UICC YY fellowship (Feng2014/YY1/315514) to XPF.

1. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. *Semin Cancer Biol* 2002; **12**: 421–429.
2. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK *et al*. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. *Int J Radiat Oncol Biol Phys* 1992; **23**: 261–270.

3. Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D *et al.* Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. *Cancer* 2004; **101**: 300–306.
4. Wang WJ, Wu SP, Liu JB, Shi YS, Huang X, Zhang QB *et al.* MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. *Cancer Res* 2013; **73**: 1219–1231.
5. Rothwarf DM, Karin M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. *Sci STKE* 1999; **1999**: RE1.
6. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. *Annu Rev Immunol* 2000; **18**: 621–663.
7. Greten FR, Karin M. NF-kB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 2005; **5**: 749–759.
8. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy. *J Clin Invest* 2005; **115**: 2625–2632.
9. Ghosh S, Karin M. Missing pieces in the NF-kB puzzle. *Cell* 2002; **109** (Suppl):S81–S96.
10. Bonizzi G, Karin M. The two NF-kB activation pathways and their role in innate and adaptive immunity. *Trends Immunol* 2004; **25**: 280–288.
11. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G *et al.* Activation by IKKa of a second, evolutionary conserved, NF-kB signaling pathway. *Science* 2001; **293**: 1495–1499.
12. Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, Vu D *et al.* Activation of IKKa target genes depends on recognition of specific kB binding sites by RelB:p52 dimers. *EMBO J* 2004; **23**: 4202–4210.
13. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL *et al.* Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. *Nature* 2007; **446**: 690–694.
14. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. *Nature* 2010; **464**: 302–305.
15. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. *Nat Rev Genet* 2007; **8**: 93–103.
16. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. *Nature* 2008; **454**: 56–61.
17. Kawai S, Amano A. BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. *J Cell Biol* 2012; **197**: 201–208.
18. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. *Nature* 2009; **460**: 529–533.
19. Yan M, Zhang Y, He B, Xiang J, Wang ZF, Zheng FM *et al.* IKKalpha restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. *Nat Commun* 2014; **5**: 3661.
20. Deng L, Li Y, Ai P, Xie Y, Zhu H, Chen N. Increase in IkappaB kinase alpha expression suppresses the tumor progression and improves the prognosis for nasopharyngeal carcinoma. *Mol Carcinog* 2013; **54**: 156–165.
21. Tang X, Zhang Y, Tucker L, Ramratnam B. Phosphorylation of the RNase III enzyme Drosha at Serine300 or Serine302 is required for its nuclear localization. *Nucleic Acids Res* 2010; **38**: 6610–6619.
22. Besse A, Sana J, Fadrus P, Slaby O. MicroRNAs involved in chemo- and radioresistance of high-grade gliomas. *Tumour Biol* 2013; **34**: 1969–1978.
23. Czochor JR, Glazer PM. microRNAs in cancer cell response to ionizing radiation. *Antioxid Redox Signal* 2014; **21**: 293–312.
24. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. *Cell* 2009; **136**: 642–655.
25. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. *Nat Rev Mol Cell Biol* 2009; **10**: 126–139.
26. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nat Rev Drug Discov* 2013; **12**: 847–865.
27. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N *et al.* The microprocessor complex mediates the genesis of microRNAs. *Nature* 2004; **432**: 235–240.
28. Morlando M, Ballarino M, Gromak N, Pagano F, Bozzoni I, Proudfoot NJ. Primary microRNA transcripts are processed co-transcriptionally. *Nat Struct Mol Biol* 2008; **15**: 902–909.
29. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev* 2004; **18**: 3016–3027.
30. Michlewski G, Guil S, Semple CA, Caceres JF. Posttranscriptional regulation of miRNAs harboring conserved terminal loops. *Mol Cell* 2008; **32**: 383–393.
31. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. *Science* 2008; **320**: 97–100.
32. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. *Mol Cell* 2010; **39**: 373–384.
33. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkB kinase-a in NF-kB-dependent gene expression. *Nature* 2003; **423**: 659–663.
34. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKKa is critical for cytokine-induced gene expression. *Nature* 2003; **423**: 655–659.
35. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB. Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. *Mol Cell* 2005; **18**: 71–82.
36. Chen C, Zhang Y, Zhang L, Weakley SM, Yao Q. MicroRNA-196: critical roles and clinical applications in development and cancer. *J Cell Mol Med* 2011; **15**: 14–23.
37. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR *et al.* High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. *World J Gastroenterol* 2009; **15**: 2089–2096.
38. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. *J Dig Dis* 2010; **11**: 50–54.
39. Braig S, Mueller DW, Rothhammer T, Bosserhoff AK. MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. *Cell Mol Life Sci* 2010; **67**: 3535–3548.
40. Li Y, Zhang M, Chen H, Dong Z, Ganapathy V, Thangaraju M *et al.* Ratio of miR-196 s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. *Cancer Res* 2010; **70**: 7894–7904.
41. Kim YJ, Bae SW, Yu SS, Bae YC, Jung JS. miR-196a regulates proliferation and osteogenic differentiation in mesenchymal stem cells derived from human adipose tissue. *J Bone Miner Res* 2009; **24**: 816–825.
42. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS *et al.* Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. *Int J Cancer* 1999; **83**: 121–126.
43. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY *et al.* Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. *Proc Natl Acad Sci USA* 1989; **86**: 9524–9528.
44. Lo AK, Liu Y, Wang XH, Huang DP, Yuen PW, Wong YC *et al.* Alterations of biologic properties and gene expression in nasopharyngeal epithelial cells by the Epstein-Barr virus-encoded latent membrane protein 1. *Lab Invest* 2003; **83**: 697–709.
45. To EW, Chan KC, Leung SF, Chan LY, To KF, Chan AT *et al.* Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. *Clin Cancer Res* 2003; **9**: 3254–3259.
46. Shanmugaratnam K, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. *Cancer* 1993; **71**: 2689–2697.
47. Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang PF *et al.* Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. *Cancer Res* 2010; **70**: 3450–3462.

Supplementary Information accompanies this paper on Cell Death and Differentiation website (http://www.nature.com/cdd)